Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]
Discontinued
Reference number: GID-TA11024
Please note that following on from advice received from the company the timelines for this appraisal have been revised. Therefore, we now anticipate that the appraisal will begin in mid-June 2024 when we will write to you about how you can get involved.